Comparative effectiveness of six Chinese herb formulas for acute exacerbation of chronic obstructive pulmonary disease: protocol for systematic review and network meta-analysis

Shaonian Liu,1,2,3,4 Jing Chen,1,2,3,4 Yihan He,1,2,3,4 Lei Wu,2,3,4,5 Jiaqi Lai,1,2,3,4 Jinhong Zuo,2 Lihong Yang,1,2,3,4 Xinfeng Guo1,2,3,4

ABSTRACT

Introduction Chinese medicine is commonly used to combine with pharmacotherapy for the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Six Chinese herb formulas involving Weijing decoction, Maxingshigan decoction, Yuebijiabanxia decoction, Qingqihuatan decoction, Dingchuan decoction and Sangbaipi decoction are recommended in Chinese medicine clinical guideline or textbook, to relieve patients with phlegm-heat according to Chinese syndrome differentiation. However, the comparative effectiveness among these six formulas has not been investigated in published randomised controlled trials. We plan to summarise the direct and indirect evidence for these six formulas combined with pharmacotherapy to determine the relative merits options for the management of AECOPD.

Methods and analysis We will perform the comprehensive search for the randomised controlled trials to evaluate the effectiveness of six Chinese herb formulas recommended in Chinese medicine clinical guideline or textbook. The combination of pharmacotherapy includes bronchodilators, antibiotics and corticosteroids that are routinely prescribed for AECOPD. The primary outcome will be lung function, arterial blood gases and length of hospital stay. The data screening and extraction will be conducted by two different reviewers. The quality of RCT will be assessed according to the Cochrane handbook risk of bias tool. The Bayes of network meta-analysis (NMA) will be conducted with WinBUGS to compare the effectiveness of six formulas. We will also use the surface under the cumulative ranking curve (SUCRA) to obtain the comprehensive rank for these treatments.

Ethics and dissemination This review does not require ethics approval and the results of NMA will be submitted to a peer-review journal.

Trial registration number PROSPERO (CRD42016052699).

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a common respiratory disease characterised by persistent airflow limitation and abnormal inflammatory response in airways.1 A recent survey reported that the estimated COPD prevalence was 6.2% in nine Asia-Pacific territories.2 This condition has resulted in an economic and social burden with the substantial morbidity and mortality worldwide.3,4 A survey estimates that COPD will become the third leading cause of death worldwide in 2030.5 Acute exacerbation of COPD is defined as the sustain worsening of the patient’s respiratory symptoms beyond normal day-to-day variations.1 It has a considerable impact on the patients’ health status, lung function and even increases the risk of death.6–8 The clinical guideline recommended pharmacological therapies for the management of acute exacerbation including bronchodilators, antibiotics, corticosteroids and some other respiratory support. Despite the effectiveness of these therapies, acute exacerbation still occurs frequently and is significantly associated with morbidity and mortality.9 Moreover,
these therapies have been associated with some side effects such as tremour, hyperglycaemia, candidiasis and antibiotic resistance. Clinicians should balance the effectiveness and safety of these pharmaceutical interventions for patients.

Chinese herb medicine is widely prescribed as an adjunct to western medicine to manage acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in clinical guideline. Although CHM is not the mainstream for treating COPD, it has become increasingly accepted as a form of complementary or complementary medicine in western countries. Chinese herb formulas combined with routine pharmacotherapy have showed the promising benefits on lung function, arterial blood gases, St George’s Respiratory Questionnaire (SGRQ) scoring and 6 min walk test (6MWT) when compared with routine pharmacotherapy alone. Six Chinese herb formulas: Weijing decoction, Maxingshigan decoction, Yuebijia-banxia decoction, Qingqihuatan decoction, Dingchuan decoction and Sangbaipi decoction are representative recipes to treat patients with AECOPD of phlegm-heat syndromes in Chinese medicine theory. Despite the difference of herb ingredients, all these formulas can be prescribed to clear phlegm-heat symptoms for the patients. They also will be modified mildly according to additional clinical symptoms. These formulas or active compounds of herb ingredients also show the effects on anti-inflammation, antioxidative stress and improve immune function which may shorten recovery time and reduce recurrence of AECOPD. Several systematic reviews synthesised the effectiveness of single formula. However, the paucity of evidence from direct comparison between these six formulas posed a challenge for clinicians to find the more effective therapeutic option.

Network meta-analyses (NMAs), a newer statistical technique, compared with the traditional pairwise meta-analysis, can evaluate the relative efficacy of multiple treatment comparisons including both direct and indirect comparisons. The combination of direct and indirect evidence may improve the precision for the estimated effect size. The major value of NMAs is that it can provide the ranking of treatment options according to their effectiveness, which is important for clinicians to make the best treatment choice.

Therefore, we plan to conduct this systematic review and NMAs to compare these six Chinese herb formulas combined with pharmacotherapy to determine their relative effectiveness and safety in the treatment of AECOPD.

METHODS AND ANALYSIS
Registration
The study protocol has been registered on international prospective register of systematic review (PROSPERO). The procedure of this protocol will be conducted according to the Preferred Reporting Item for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidance.

Eligibility criteria
Type of study
We will include all the randomised controlled trials that investigated the effectiveness of six Chinese herb formulas combined with pharmacotherapy for the treatment of AECOPD.

Participants
COPD should be confirmed according to the standard diagnostic criteria including the Global Initiative for Chronic Obstructive Lung Disease (GOLD); the British Thoracic Society, the American Thoracic Society, the European Respiratory Society or Chinese COPD guideline.

Patients must be aged at least 18 years old and diagnosed as AECOPD with one or more following symptoms: increased cough frequency, increased sputum volume, increased dyspnoea. We will exclude studies of participants with other respiratory disease like asthma, bronchiectasia, pulmonary tuberculosis and so on.

Interventions and comparators
Interventions involving the combination of Chinese herb formulas with conventional pharmacotherapy are eligible. The interested Chinese medicine therapies include the following six formulas: Weijing decoction, Maxingshigan decoction, Yuebijia-banxia decoction, Qingqihuatan decoction, Dingchuan decoction and Sangbaipi decoction. The same conventional pharmacotherapy must be used in the comparator arm.

Outcome
The primary outcomes include: (1) lung function—forced expiratory volume in 1 s (FEV1), (2) arterial blood gases—PaO2 of oxygen (PaO2) and carbon dioxide (PaCO2), (3) length of hospital stay.

The secondary outcomes include: (1) dyspnoea, (2) health-related quality of life, (3) hospital readmission for acute exacerbation, (4) effective rate and (5) adverse events.

Search strategy
We will perform the comprehensive search in both English and Chinese database involving PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, AMED, Chinese Biomedical Database (CBM), Chinese National Knowledge Infrastructure (CNKI), Chongqing VIP information (CQVIP) and Wanfang database, from their inceptions to December 2016. The following sources will also be searched to identify clinical trials which are in progress or completed: ClinicalTrials.gov and WHO clinical trials registry. The additional relevant studies will also be retrieved from the reference lists of systematic reviews and included studies. We will map search terms to controlled vocabulary if possible. In addition, the search strategy for selecting the fields of title, abstract or keyword will be different referring to the characteristics of databases. Search terms are grouped into three blocks (see table 1).
### Table 1  Search terms

| Search block | Search terms |
|--------------|--------------|
| Participants | Pulmonary Disease, Chronic Obstructive OR Bronchitis, Chronic OR Pulmonary Emphysema OR Emphysema OR COPD OR Chronic Obstructive Pulmonary OR COAD OR Chronic Obstructive Airway OR Chronic Obstructive Lung OR Chronic obstructive bronchopulmonary OR Chronic obstructive respiratory OR Chronic Airflow Obstruction OR Chronic Airflow Obstructive OR Chronic bronchitis OR Pulmonary emphysema OR Lung emphysema OR Chronic Airflow limitation. |
| Intervention | weijing decoction OR weijing tang OR sangbaipi decoction OR sangbaipi tang OR maxingshigan decoction OR maxingshigan tang OR yuebijiabanxia decoction OR yuebijiabanxia tang OR dingchuan decoction OR dingchuan tang OR qingqihuatan decoction OR qingqihuatan tang OR qingqihuatan pill |
| Study design | Randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR drug therapy OR randomly OR trial OR groups |

### Study selection and data extraction

Literature retrieved citations will be managed by EndNote X6 software. Two independent reviewers (JL and JZ) will assess the title and abstract of the literature after removing duplications. The further screening will be performed to select eligible articles by reviewing the full-text. Any disagreement between the reviewers will be resolved by discussion with a third person (JC). The selection process will be provided in a PRISMA flow chart (see figure 1).

We will design the standardised database sheet for data extraction. Epidata software 3.1 (The EpiData Association, Odense, Denmark, 2003–2008) will be used to extract data and check the consistency of information.

### Risk of bias assessment

The methodological quality of the eligible studies will be evaluated according to the Cochrane collaboration’s risk of bias tool. The assessment details include: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting...

---

**Figure 1** Flow chart of searching and screening studies.
and other sources of bias. Each domain will be assessed as ‘low risk’ or ‘high risk’ or ‘unclear risk’ according to the description details of eligible studies. Any discrepancies will be further discussed with a third reviewer (YH).

Statistical analysis
Pairwise meta-analysis
The conventional pairwise meta-analysis will be performed using random-effects model by Revman 5.3 software. Dichotomous data are presented as relative risk (RR) with 95% CI and continuous data are reported as mean difference (MD) with 95% CI. The χ² test and I² test will be conducted to convey the potential heterogeneity.

Network meta-analysis
The NMA will be conducted in a Bayesian hierarchical framework using the Markov Chain Monte Carlo (MCMC) algorithm by WinBUGS 1.4.3 software. The statistical heterogeneity of entire NMA will be investigated by the magnitude of heterogeneity variance (τ²) estimated from the NMA model. If the direct evidence is available, the combined estimation will be provided for NMA. There are several methods to evaluate the potential difference in treatment effect estimated by direct and indirect comparisons. We will apply node splitting method to explore the inconsistency of the model. The deviance information criterion (DIC) will be used to assess the model fitness by comparing the fixed and random effects model and the lower DIC is preferred. To rank the probabilities of the best intervention for various treatments, we will use surface under the cumulative ranking curve (SUCRA) and the mean ranks. SUCRA will be described with percentages, and larger values indicate the better ranks for the treatment. The generation of NMA graphs and result figures will be performed by Stata software (Stata V.12). If the data are not available for quantitative analysis, we will describe and summarise the evidence.

Sensitivity analysis and subgroup analysis
The strategies employed to address the heterogeneity of pairwise meta-analysis also can be used in network analysis to tackle inconsistency. If the heterogeneity or inconsistency among the studies was detected, subgroup analysis will be conducted according to the effect modifiers, including sample size, severity of COPD, treatment duration. Also, the network meta-regression will be performed to explore the possible sources of inconsistency. We will perform the sensitivity analysis to explore the robust conclusions of primary outcomes if feasible. Different levels of the methodological quality of studies will influence the overall effects. Sensitivity analysis will be conducted by removing trails that report the non-random sequence generation.

Publication bias
Egger’s regression test will be performed to assess the publication bias of the included studies. If feasible, we will also convey whether the small study effects exist in a network of interventions by the statistical model.

Quality of evidence
We will also assess the quality of evidence for the main outcomes with the GRADE (the Grading of Recommendations Assessment, Development and Evaluation) approach. The five items will be investigated, including limitations in study design, inconsistency, imprecision, indirectness and publication bias.

DISCUSSION
Chinese medicine has been used more than thousands of years for the treatment of respiratory condition. Nowadays, Chinese herb formula is commonly used as adjuvant therapy for the management of AECOPD in China. Multiple Chinese herb formulas are recommended in clinical guideline or textbook, while different formulas for each Chinese syndrome. Although few studies have reviewed the effective of the individual formula, the relative therapeutic effect differences among these formulas are still uncertain. Therefore, we plan to conduct NMA to evaluate the comparative effectiveness of different Chinese herb formulas. This will be the first review to compare the effectiveness of six most commonly used Chinese herb formulas for the treatment of AECOPD. We hope that the results of our study will provide the clinical recommendation for patients with AECOPD in Chinese medicine clinical practice, and promote evidence-based for clinical Chinese medicine.

Ethics and dissemination
This review does not require the ethical approval since the study bases on the published evidence. The results of NMA will be reported according to the PRISMA extension statement for reporting of systematic reviews incorporating NMA and submitted to a peer-review journal.

Contributors SL, XG and LW conceived and designed this study. SL and JC drafted the protocol. JL and JZ will conduct the search, data screening and extraction. SL, JC, YH, LW, LY and XG have critically reviewed the manuscript and approved it for publication.

Funding This study is supported by Guangdong Provincial Department of Science and Technology, Guangdong, China (the project grant no 2014A020221020) and Clinical Research Special Project of Guangdong Provincial Hospital of Chinese Medicine (grant no YN2014LN10).

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement This is a study protocol of network meta-analysis. No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
REFERENCES

1. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease: GOLD, 2016. http://www.goldcopd.org

2. Lim S, Lam DC, Muttalif AR, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med 2015;14:4.

3. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397–412.

4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.

5. World Health Organization. Chronic respiratory diseases, burden of disease from 2002 to 2030. BMJ Open 2017;7:e017099. doi:10.1136/bmjopen-2017-017099